Hong Kong Stock Movers: HENLIUS Surges Over 8% as 8 Research Findings Set for WCLC, Han Si Zhuang Enters NHS Coverage

Stock News15:12

HENLIUS (02696) shares continued their upward momentum, rising over 8% in today's trading, bringing the weekly gain to more than 20%. As of the latest update, the stock was trading at 67.2 Hong Kong dollars, up 8.47%, with a turnover of 28.22 million Hong Kong dollars.

On the news front, the 2026 World Conference on Lung Cancer (WCLC) is scheduled to take place from September 12 to 15 in Seoul, South Korea. HENLIUS will present a range of new research results for its innovative products at this conference, including Phase I study data for the PD-L1 ADC HLX43 in thymic squamous cell carcinoma (TSCC), as well as seven research datasets for the anti-PD-1 monoclonal antibody, Han Si Zhuang, covering extensive-stage small cell lung cancer, limited-stage small cell lung cancer, and pulmonary large cell neuroendocrine carcinoma.

Notably, HENLIUS's independently developed anti-PD-1 monoclonal antibody, Han Si Zhuang, has recently received a recommendation from the UK's National Institute for Health and Care Excellence (NICE), positioning it for potential inclusion in the National Health Service (NHS) to benefit patients with extensive-stage small cell lung cancer (ES-SCLC).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment